Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates

被引:73
作者
Verthelyi, D
Klinman, DM
机构
[1] US FDA, Ctr Biol Evaluat & Res, Sect Retroviral Immunol, Bethesda, MD 20892 USA
[2] US FDA, Div Therapeut Prot, Bethesda, MD 20892 USA
关键词
innate immunity; CpG ODN; primates; human; vaccines; immunoprotection; allergies; cancer; safety;
D O I
10.1016/S1521-6616(03)00202-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oligodeoxynucleotides (ODN) containing CpG motifs mimic the ability of microbial DNA to activate the innate immune system. The resultant response limits the early spread of infectious organisms while promoting the development of adaptive immunity. CpG ODN show promise as vaccine adjuvants and in the treatment of asthma, allergy, infection, and cancer. Due to evolutionary divergence in CpG recognition between species, CpG ODN that are most active in rodents are poorly immunostimulatory in primates. Thus, evidence that CpG ODN have therapeutic activity in mice must be confirmed in primates. Two distinct types of CpG ODN were identified that stimulate primate PBMC. D-type ODN trigger plasmacytoid DC to secrete IFNalpha, monocytes to mature into functionally active DC, and NK cells to secrete IFNgamma. K-type ODN stimulate B cells and monocytes to proliferate and secrete IgM, IL-10, and/or IL-6. In vivo studies in nonhuman primates indicate that proinflammatory or humoral immune responses can be selectively facilitated by judicious use of these distinct types of ODN.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 77 条
[1]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[2]  
2-U
[3]   CONTROLLED FIELD TRIALS OF A VACCINE AGAINST NEW-WORLD CUTANEOUS LEISHMANIASIS [J].
ANTUNES, CM ;
MAYRINK, W ;
MAGALHAES, PA ;
COSTA, CA ;
MELO, MN ;
DIAS, M ;
MICHALICK, MSM ;
WILLIAMS, P ;
LIMA, AO ;
VIEIRA, JBF ;
SCHETTINI, APM .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1986, 15 (04) :572-580
[4]   Chlamydia infections and heart disease linked through antigenic mimicry [J].
Bachmaier, K ;
Neu, N ;
de la Maza, LM ;
Pal, S ;
Hessel, A ;
Penninger, JM .
SCIENCE, 1999, 283 (5406) :1335-1339
[5]   Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs [J].
Ballas, ZK ;
Krieg, AM ;
Warren, T ;
Rasmussen, W ;
Davis, HL ;
Waldschmidt, M ;
Weiner, GJ .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :4878-4886
[6]   DNA activates human immune cells through a CpG sequence-dependent manner [J].
Bauer, M ;
Heeg, K ;
Wagner, H ;
Lipford, GB .
IMMUNOLOGY, 1999, 97 (04) :699-705
[7]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
[8]   CpG motifs as possible adjuvants for the treatment of allergic diseases [J].
Bohle, B .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2002, 129 (03) :198-203
[9]  
Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO
[10]  
2-R